56472-29-8
中文名称
2-羟基乳清酸
英文名称
2-HYDROXYOLEICACID
CAS
56472-29-8
分子式
C18H34O3
分子量
298.46
MOL 文件
56472-29-8.mol
更新日期
2023/03/20 15:41:29
56472-29-8 结构式
基本信息
中文别名
2-羟基油酸2-羟基乳清酸
2-羟基乳清酸-D17
英文别名
2OHOAMinerval
Acumapimod
-d17 Minerva-d17l
2-HYDROXYOLEICACID
α-Hydroxyoleic Acid
α-Hydroxyoleic Acid-d17
cis-2-Hydroxy-9-octadecenoic Acid
(Z)-2-Hydroxyoctadec-9-enoic acid
(9Z)-2-Hydroxy-9-octadecenoic Acid
所属类别
生物化工：激动剂抑制剂物理化学性质
熔点47-50oC
储存条件room temp
溶解度二甲基亚砜：>20mg/mL
形态固体
颜色白色至棕褐色
InChI1S/C18H34O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h9-10,17,19H,2-8,11-16H2,1H3,(H,20,21)/b10-9-
InChIKeyJBSOOFITVPOOSY-KTKRTIGZSA-N
SMILESCCCCCCCC\C=C/CCCCCCC(O)C(O)=O
2-羟基乳清酸价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-129467 | 2-羟基乳清酸 (Rac)-Idroxioleic acid | 56472-29-8 | 1 mg | 650元 |
| 2026/09/15 | HY-129467 | 2-羟基乳清酸 (Rac)-Idroxioleic acid | 56472-29-8 | 5 mg | 1300元 |
| 2026/09/15 | HY-129467 | 2-羟基乳清酸 (Rac)-Idroxioleic acid | 56472-29-8 | 10 mM * 1 mLin DMSO | 1430元 |
常见问题列表
生物活性
Minerval (2-Hydroxyoleic acid) 是一种合成油酸 (OA) 衍生物，能与质膜结合改变脂质组织。Minerval 具有抗肿瘤作用。体外研究
Minerval (25-75 μM; 72 hours) impairs Jurkat cell growth in a time- and concentration-dependent manner, with an IC
50
of ~40 μM.
Minerval (25-50 μM; 72 hours) also induces a marked and concentration-dependent increase in the proteolytic cleavage of PARP, a molecular marker of apoptosis.
Cell Viability Assay
| Cell Line: | Jurkat cells |
| Concentration: | 25 μM, 50 μM, 75 μM |
| Incubation Time: | 24 hours, 48 hours, 72 hours |
| Result: | Impaired Jurkat cell growth in a time- and concentration-dependent manner. |
Western Blot Analysis
| Cell Line: | Jurkat cells |
| Concentration: | 25 μM, 50 μM |
| Incubation Time: | 72 hours |
| Result: | Induced a marked and concentration-dependent increase in the proteolytic cleavage of PARP. |
体内研究
Minerval markedly and significantly inhibits tumour growth in nude mice infected with Jurkat cells.
| Animal Model: | 6-week-old nude male mice (Jurkat cells xenograft model) |
| Dosage: | 600 mg/kg |
| Administration: | Oral administration; daily; for 21 days |
| Result: | Markedly and significantly inhibited tumour growth. |